LLY

715.06

-1.34%↓

JNJ

152.52

-0.44%↓

ABBV

182.34

+0.35%↑

NVO

68.13

-0.07%↓

UNH

296.46

-2.25%↓

LLY

715.06

-1.34%↓

JNJ

152.52

-0.44%↓

ABBV

182.34

+0.35%↑

NVO

68.13

-0.07%↓

UNH

296.46

-2.25%↓

LLY

715.06

-1.34%↓

JNJ

152.52

-0.44%↓

ABBV

182.34

+0.35%↑

NVO

68.13

-0.07%↓

UNH

296.46

-2.25%↓

LLY

715.06

-1.34%↓

JNJ

152.52

-0.44%↓

ABBV

182.34

+0.35%↑

NVO

68.13

-0.07%↓

UNH

296.46

-2.25%↓

LLY

715.06

-1.34%↓

JNJ

152.52

-0.44%↓

ABBV

182.34

+0.35%↑

NVO

68.13

-0.07%↓

UNH

296.46

-2.25%↓

Search

Regeneron Pharmaceuticals Inc

Chiusa

SettoreSettore sanitario

596.38 -1.47

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

591.89

Massimo

604.94

Metriche Chiave

By Trading Economics

Entrata

-109M

809M

Vendite

-761M

3B

P/E

Media del settore

15.175

54.533

EPS

8.22

Rendimento da dividendi

0.59

Margine di Profitto

26.701

Dipendenti

15,158

EBITDA

-54M

1B

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+31.95% upside

Dividendi

By Dow Jones

Rendimento da dividendi

Media del settore

0.59%

2.41%

Utili prossimi

31 lug 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-10B

64B

Apertura precedente

597.85

Chiusura precedente

596.38

Notizie sul Sentiment di mercato

By Acuity

44%

56%

160 / 382 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Very Strong Bearish Evidence

Regeneron Pharmaceuticals Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

19 mag 2025, 11:55 UTC

Acquisizioni, Fusioni, Takeovers

Regeneron to Buy 23andMe Out of Bankruptcy for $256 Million

29 apr 2025, 11:07 UTC

Utili

Regeneron 1Q Profit Rises, Revenue Falls; FY25 CapEx Target Trimmed

4 feb 2025, 12:13 UTC

Utili

Regeneron 4Q Revenue Up on Strong Sales of EYLEA HD

19 mag 2025, 17:52 UTC

Notizie principali
Acquisizioni, Fusioni, Takeovers

Regeneron to Buy 23andMe Out of Bankruptcy for $256 Million -- 2nd Update

19 mag 2025, 16:13 UTC

Acquisizioni, Fusioni, Takeovers

Regeneron Is Buying 23andMe. The Deal Is a Head Scratcher. -- Barrons.com

19 mag 2025, 14:42 UTC

Notizie principali
Acquisizioni, Fusioni, Takeovers

Regeneron to Buy 23andMe Out of Bankruptcy for $256 Million -- 2nd Update

19 mag 2025, 13:33 UTC

Notizie principali
Acquisizioni, Fusioni, Takeovers

Regeneron to Buy 23andMe Out of Bankruptcy for $256 Million -- Update

19 mag 2025, 11:10 UTC

Acquisizioni, Fusioni, Takeovers

Regeneron: To Ensure Compliance With 23andMe Consumer Privacy Policies, Applicable Laws on Customer Data >REGN

19 mag 2025, 11:10 UTC

Acquisizioni, Fusioni, Takeovers

Regeneron: 23andMe Transaction Expected to Close in 3Q >REGN

19 mag 2025, 11:09 UTC

Acquisizioni, Fusioni, Takeovers

Regeneron: To Continue All 23andMe Consumer Genome Services Uninterrupted >REGN

19 mag 2025, 11:08 UTC

Acquisizioni, Fusioni, Takeovers

Regeneron: Named Successful Bidder in Bankruptcy Auction for Substantially All Assets of 23andMe >REGN

29 apr 2025, 18:04 UTC

Discorsi di Mercato
Utili

Regeneron Sinks As Sales Of Key Eye Medication Tumble -- Market Talk

29 apr 2025, 14:39 UTC

Discorsi di Mercato
Utili

Regeneron's Eylea Setback Drags Stock as Investor Frustrations Mount -- Market Talk

29 apr 2025, 14:29 UTC

Utili

Regeneron Stock Plummets After Earnings Miss -- Barrons.com

29 apr 2025, 13:11 UTC

Utili

Regeneron Stock Plummets After Earnings Miss -- Barrons.com

29 apr 2025, 10:32 UTC

Utili

Regeneron Pharma Cuts 2025 CapEx to $850M-$950M >REGN

29 apr 2025, 10:30 UTC

Utili

Regeneron Pharma 1Q Rev $3.03B >REGN

29 apr 2025, 10:30 UTC

Utili

Regeneron Pharma 1Q Net $808.7M >REGN

29 apr 2025, 10:30 UTC

Utili

Regeneron Pharma 1Q EPS $7.27 >REGN

29 apr 2025, 10:30 UTC

Utili

Regeneron Pharma 1Q Adj EPS $8.22 >REGN

22 apr 2025, 10:51 UTC

Notizie principali

Drug Companies Step Up 'Make in America' Plans to Counter Tariffs -- WSJ

28 feb 2025, 12:00 UTC

Notizie principali

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

4 feb 2025, 11:58 UTC

Utili

Regeneron 4Q Rev Up on Strong Sales of EYLEA HD

4 feb 2025, 11:37 UTC

Utili

Regeneron Pharma Sees 2025 Adjusted R&D $5B-$5.2B >REGN

4 feb 2025, 11:37 UTC

Utili

Regeneron Pharma Sees 2025 Gross Margin on Net Product Sales 87%-88% >REGN

4 feb 2025, 11:36 UTC

Utili

Regeneron Pharma Sees 2025 Capital Spending $850M-$975M >REGN

4 feb 2025, 11:35 UTC

Utili

Regeneron Pharma Declares Initial Quarterly Dividend of 88c >REGN

4 feb 2025, 11:35 UTC

Utili

Regeneron Pharma 4Q Adj EPS $12.07 >REGN

4 feb 2025, 11:34 UTC

Utili

Regeneron Pharma 4Q U.S. Net Sales for Eylea HD, Eylea Rose 2% to $1.5B >REGN

4 feb 2025, 11:34 UTC

Utili

Regeneron Pharma: 4Q Dupixent Global Net Sales Recorded by Sanofi Rose 15% to $3.7B >REGN

Confronto tra pari

Modifica del prezzo

Regeneron Pharmaceuticals Inc Previsione

Obiettivo di Prezzo

By TipRanks

31.95% in crescita

Previsioni per 12 mesi

Media 811.21 USD  31.95%

Alto 979 USD

Basso 535 USD

Basato su 21 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Regeneron Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

21 ratings

18

Acquista

2

Mantieni

1

Vendi

Punteggio Tecnico

By Trading Central

542.44 / 599.76Supporto e resistenza

A breve termine

Very Strong Bearish Evidence

A termine intermedio

Strong Bullish Evidence

A lungo termine

Weak Bearish Evidence

Sentiment

By Acuity

160 / 382 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove rialziste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sopra la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.